Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI).

Authors: Joseph J. Park, Lauren Howard, Stamatina Fragkogianni, Daniel J. George, Andrew J. Armstrong

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e17085

Source: Full article

---

Abstract

e17085